PCI Pharma Services (PCI) has expanded its global clinical footprint with the new Clinical Center of Excellence (COE) in Western Europe at its Berlin location. This is part of PCI’s global strategy to expand its clinical supply-chain network into continental Europe to complement offerings at its UK and Ireland sites. The COE is expected to be completed in January 2021.

The investment will represent a new flagship site and will include 17,000 square feet of space dedicated to primary and secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution. This capacity aims to service the EU-based clinical trials ecosystem, which currently has more than 38,100 active trials sites throughout the 27-member countries and is second only to the U.S. for such research.   

“Our strategy has always been to increase the capacity and capabilities of our clinical trial services network, and with the acquisition of Bellwyck Pharma Services earlier this year, we are taking the next step to enhance our capabilities at our new Berlin facility to support the growing clinical trial market in Europe and beyond,” said Salim Haffar, chief executive officer, PCI Pharma Services. “This investment will provide clients with global clinical trial solutions for their life-changing medicines, ensuring continuity of patient supply to match growing market demands.”